Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Immunologic Deficiency Syndrome Epidemiology Forecast

DelveInsight's "Immunologic Deficiency Syndrome - Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted Immunologic Deficiency Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018-2030

Immunologic Deficiency Syndrome Understanding

The DelveInsight Immunologic Deficiency Syndrome epidemiology report gives a thorough understanding of the Immunologic Deficiency Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Immunologic Deficiency Syndrome in the US, Europe, and Japan. The report covers the detailed information of the Immunologic Deficiency Syndrome epidemiology scenario in seven major countries (US, EU5, and Japan).

Immunologic Deficiency Syndrome Epidemiology Perspective by DelveInsight

The Immunologic Deficiency Syndrome epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Immunologic Deficiency Syndrome epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Immunologic Deficiency Syndrome epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2018 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Immunologic Deficiency Syndrome Detailed Epidemiology Segmentation

The Immunologic Deficiency Syndrome epidemiology covered in the report provides historical as well as forecasted Immunologic Deficiency Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018 to 2030.


The DelveInsight Immunologic Deficiency Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Immunologic Deficiency Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Immunologic Deficiency Syndrome Epidemiology Report and Model provide an overview of the global trends of Immunologic Deficiency Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Immunologic Deficiency Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Immunologic Deficiency Syndrome
  • The report provides the segmentation of the Immunologic Deficiency Syndrome epidemiology

Report Highlights

  • 11-year Forecast of Immunologic Deficiency Syndrome epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Immunologic Deficiency Syndrome
  • Cases of Immunologic Deficiency Syndrome by Mutation Types
  • Immunologic Deficiency Syndrome Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Immunologic Deficiency Syndrome?
  • What are the key findings pertaining to the Immunologic Deficiency Syndrome epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2018-2030)?
  • What would be the total number of patients of Immunologic Deficiency Syndrome across the 7MM during the forecast period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2018-2030)?
  • What is the disease risk, burden and unmet needs of Immunologic Deficiency Syndrome?
  • What are the currently available treatments of Immunologic Deficiency Syndrome?

Reasons to buy

The Immunologic Deficiency Syndrome Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Immunologic Deficiency Syndrome market
  • Quantify patient populations in the global Immunologic Deficiency Syndrome market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Immunologic Deficiency Syndrome therapeutics in each of the markets covered
  • Understand the magnitude of Immunologic Deficiency Syndrome population by its epidemiology
  • The Immunologic Deficiency Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Immunologic Deficiency Syndrome

3. Immunologic Deficiency Syndrome: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Immunologic Deficiency Syndrome Epidemiology Scenario in the 7MM (2018- 2030)

5.4. United States Epidemiology

5.4.1. Immunologic Deficiency Syndrome Epidemiology Scenario in the United States (2018- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Immunologic Deficiency Syndrome Epidemiology Scenario in Germany (2018- 2030)

5.5.2. France Epidemiology

5.5.2.1. Immunologic Deficiency Syndrome Epidemiology Scenario in France (2018- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Immunologic Deficiency Syndrome Epidemiology Scenario in Italy (2018- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Immunologic Deficiency Syndrome Epidemiology Scenario in Spain (2018- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Immunologic Deficiency Syndrome Epidemiology Scenario in the United Kingdom (2018-2030)

5.6. Japan Epidemiology

5.6.1. Immunologic Deficiency Syndrome Epidemiology Scenario in Japan (2018- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Immunologic Deficiency Syndrome Treatment and Management

6.2. Immunologic Deficiency Syndrome Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

List of Tables

Table 1:  Immunologic Deficiency Syndrome Epidemiology in 7MM (2018-2030)

Table 2: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in 7MM (2018-2030)

Table 3: Immunologic Deficiency Syndrome Epidemiology in the United States (2018-2030)

Table 4: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in the United States (2018-2030)

Table 5: Immunologic Deficiency Syndrome Epidemiology in Germany (2018-2030)

Table 6: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Germany (2018-2030)

Table 7: Immunologic Deficiency Syndrome Epidemiology in France (2018-2030)

Table 8: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in France (2018-2030)

Table 9: Immunologic Deficiency Syndrome Epidemiology in Italy (2018-2030)

Table 10: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Italy (2018-2030)

Table 11: Immunologic Deficiency Syndrome Epidemiology in Spain (2018-2030)

Table 12: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Spain (2018-2030)

Table 13: Immunologic Deficiency Syndrome Epidemiology in the United Kingdom (2018-2030)

Table 14: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in the United Kingdom (2018-2030)

Table 15: Immunologic Deficiency Syndrome Epidemiology in Japan (2018-2030)

Table 16: Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Japan (2018-2030)

List of Figures

Figure 1 Immunologic Deficiency Syndrome Epidemiology in 7MM (2018-2030)

Figure 2 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in 7MM (2018-2030)

Figure 3 Immunologic Deficiency Syndrome Epidemiology in the United States (2018-2030)

Figure 4 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in the United States (2018-2030)

Figure 5  Immunologic Deficiency Syndrome Epidemiology in Germany (2018-2030)

Figure 6  Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Germany (2018-2030)

Figure 7  Immunologic Deficiency Syndrome Epidemiology in France (2018-2030)

Figure 8 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in France (2018-2030)

Figure 9 Immunologic Deficiency Syndrome Epidemiology in Italy (2018-2030)

Figure 10 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Italy (2018-2030)

Figure 11 Immunologic Deficiency Syndrome Epidemiology in Spain (2018-2030)

Figure 12 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Spain (2018-2030)

Figure 13 Immunologic Deficiency Syndrome Epidemiology in the United Kingdom (2018-2030)

Figure 14 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in the United Kingdom (2018-2030)

Figure 15 Immunologic Deficiency Syndrome Epidemiology in Japan (2018-2030)

Figure 16 Immunologic Deficiency Syndrome Diagnosed and Treatable Cases in Japan (2018-2030)

*The table of contents is not exhaustive; will be provided in the final report


Forward to Friend

Need A Quote